Feature | March 14, 2014

27 U.S. Proton Therapy Centers Expected by 2017

proton therapy radiation therapy

March 14, 2014 — Research and Markets have announced the addition of the "US Proton Therapy Outlook 2017."? Physicians, in the face of an alarmingly rising incidences of cancer and limited treatment options are being forced to look for treatments beyond the conventional ones. In such a scenario, proton therapy is being projected as the Rolls Royce of radiation oncology. Unfortunately, access to proton therapy is limited for many patients due to the low number of proton therapy centers. Hence, many research institutes and hospitals are now investing in proton therapy to make it more accessible to patients.

According to the U.S. Proton Therapy Outlook 2017, the United States will be home to almost 27 such centers by 2017, a number, which is almost double the current figure. Consequentially, the market will breach the billion dollar mark to attain revenue of $1.17 Billion by 2017. The following 65 pages report provides an insight into the cancer demographics of U.S. and the various possible causes for a high incidence there. The document covers the historical trend (2008-2013) of cancer incidences, deaths and prevalence along with statewide and site-wide cancer incidences in the country.

The research covers the key companies developing or with already commissioned systems, including Hitachi, IBA, Mevion Medical Systems and Varian.

It describes the various types of radiation therapies, which can be used to treat cancer, as well as their disadvantages. Special attention has been given on proton therapy and its benefits that make it stand out amidst the conventional treatment options. The study dedicates a complete chapter on the various components of any proton therapy center and covers issues related to accelerators, delivery, transportation, planning and positioning systems to human resources required to setup a center.

As for the market, the report provides the statewide distribution of proton therapy centers in the U.S. A thorough analysis has been done on the existing and upcoming proton therapy centers to measure the market size and its future condition. The report further provides the state-wise statistics of potential patients for proton therapy and the latter's current market penetration. This is then followed by a section dedicated to market opportunity assessment, which would help service providers and vendors to extract benefits from the largely untapped but lucrative market.

For more information: www.reseasrchandmarkets.com

Related Content

RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...